Aya Inaba

Yokohama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome.

Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome.

Journal: Pediatric nephrology (Berlin, Germany)

Published: February 12, 2026

Clinical and Genetic Insights Into Isolated Proteinuria With CUBN Variants.

Clinical and Genetic Insights Into Isolated Proteinuria With CUBN Variants.

Journal: Kidney international reports

Published: December 12, 2025

Long-term outcome of mycophenolate mofetil after a single dose of rituximab in childhood-onset refractory idiopathic nephrotic syndrome.

Long-term outcome of mycophenolate mofetil after a single dose of rituximab in childhood-onset refractory idiopathic nephrotic syndrome.

Journal: Clinical and experimental nephrology

Published: February 01, 2025

A digest of the clinical practice guideline for pediatric idiopathic nephrotic syndrome 2020 updated: medical therapy.

A digest of the clinical practice guideline for pediatric idiopathic nephrotic syndrome 2020 updated: medical therapy.

Journal: Clinical and experimental nephrology

Published: January 27, 2025

Rituximab-induced long-term remission in childhood-onset, uncomplicated, frequently relapsing or steroid-dependent nephrotic syndrome: a randomized, placebo-controlled trial and a follow-up study.

Rituximab-induced long-term remission in childhood-onset, uncomplicated, frequently relapsing or steroid-dependent nephrotic syndrome: a randomized, placebo-controlled trial and a follow-up study.

Journal: Scientific reports

Published: January 26, 2025

Relationship between clinical and pathologic findings and the presence of genetic variants in patients with steroid-resistant nephrotic syndrome.

Relationship between clinical and pathologic findings and the presence of genetic variants in patients with steroid-resistant nephrotic syndrome.

Journal: Pediatric nephrology (Berlin, Germany)

Published: November 29, 2024

Efficacy of rituximab and risk factors for poor prognosis in patients with childhood-onset steroid-resistant nephrotic syndrome: a multicenter study.

Efficacy of rituximab and risk factors for poor prognosis in patients with childhood-onset steroid-resistant nephrotic syndrome: a multicenter study.

Journal: Pediatric nephrology (Berlin, Germany)

Published: February 19, 2024

Recovery from rituximab-associated persistent hypogammaglobulinaemia in children with nephrotic syndrome.

Recovery from rituximab-associated persistent hypogammaglobulinaemia in children with nephrotic syndrome.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: February 09, 2024

Two adolescents with frequently relapsing nephrotic syndrome newly diagnosed after SARS-CoV-2 vaccination: case report and literature review.

Two adolescents with frequently relapsing nephrotic syndrome newly diagnosed after SARS-CoV-2 vaccination: case report and literature review.

Journal: CEN case reports

Published: February 06, 2024

Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome: a multicenter single-arm clinical trial (JSKDC11 trial).

Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome: a multicenter single-arm clinical trial (JSKDC11 trial).

Journal: Clinical and experimental nephrology

Published: August 01, 2023

Multinucleated podocytes as a clue to diagnosis of juvenile nephropathic cystinosis.

Multinucleated podocytes as a clue to diagnosis of juvenile nephropathic cystinosis.

Journal: Pediatric nephrology (Berlin, Germany)

Published: March 30, 2023

Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease.

Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease.

Journal: Pediatric nephrology (Berlin, Germany)

Published: April 15, 2022

Showing 1-12 of 16

Last Updated: 09/26/2026